Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―
Circulation Journal · 25.12.2024 · 89 (1) · 130-138
DOI: 10.1253/circj.cj-24-0501 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Circulation Journal, erschienen am 25.12.2024. Verfasst von Hiroaki Kitaoka und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University. Hauptthemen laut MEDLINE: Benzylamines, Cardiomyopathy, Hypertrophic, Uracil. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University.
- Department of Cardiology, Keio University School of Medicine.
- Department of Cardiovascular Medicine, Showa University Fujigaoka Hospital.
- Department of Cardiology, Teikyo University Hospital.
- Department of Cardiology, Sakakibara Heart Institute.
- Division of Cardiology, Cardiovascular Center, Showa University Koto Toyosu Hospital.
Förderung
- Bristol Myers Squibb
Zitieren
APA
Kitaoka, H., Ieda, M., Ebato, M., Kozuma, K., Takayama, M., Tanno, K., Komiyama, N., Sakata, Y., Maekawa, Y., Minami, Y., Ogimoto, A., Takaya, T., Yasuda, S., Amiya, E., Furukawa, Y., Watanabe, T., Hiraya, D., Miyagoshi, H., Kinoshita, G., …, & Izumi, C. (2024). Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―. Circulation Journal, 89(1), 130-138. https://doi.org/10.1253/circj.cj-24-0501
Vancouver
Kitaoka H, Ieda M, Ebato M, Kozuma K, Takayama M, Tanno K, et al. Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―. Circulation Journal. 2024;89(1):130-138. doi:10.1253/circj.cj-24-0501
BibTeX
@article{Kitaoka2024,
author = {Kitaoka, Hiroaki and Ieda, Masaki and Ebato, Mio and Kozuma, Ken and Takayama, Morimasa and Tanno, Kaoru and Komiyama, Nobuyuki and Sakata, Yasushi and Maekawa, Yuichiro and Minami, Yuichiro and Ogimoto, Akiyoshi and Takaya, Tomofumi and Yasuda, Satoshi and Amiya, Eisuke and Furukawa, Yutaka and Watanabe, Tetsuya and Hiraya, Daigo and Miyagoshi, Hidetaka and Kinoshita, Gen and Reedy, Alison and Hegde, Sheila M and Florea, Victoria and Izumi, Chisato},
title = {Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―},
journal = {Circulation Journal},
year = {2024},
volume = {89},
number = {1},
pages = {130--138},
doi = {10.1253/circj.cj-24-0501}
}
EUVIMED